Confidential Treatment
Requested. Confidential portions of this document have been
redacted and separately filed with the
Commission.
SECOND EXTENSION
AGREEMENT
Between
YEDA RESEARCH AND DEVELOPMENT CO.
LTD.
of P.O. Box 95, Rehovot 76100,
Israel
(hereinafter "Yeda")
and
XTL BIOPHARMACEUTICALS
LTD.
of Kiryat Weizmann PO Box 370
Rehovot 76100, Israel
(hereinafter "the
Company")
|
WHEREAS
|
Yeda and the
Company have entered into a Research and Licence Agreement dated
April 7, 1993 (hereinafter “the Main Agreement”) which
was extended in an Amendment of the Research and Licence Agreement
on August 31, 1995 (hereinafter "the Amendment Agreement");
and
|
|
WHEREAS
|
Yeda and the
Company desire to further extend the Research Period and agree to
the 1997 Budget and the 1997 Research Plan (as these terms are
hereinafter defined) for said period;
|
NOW THEREFORE
IT IS AGREED BY THE PARTIES HERETO AS FOLLOWS:
The Appendices listed below which are attached
hereto shall constitute an integral part hereof:
Appendix 1 - the 1997 Research
Programme
Appendix 2 - the 1997 Research Budget
|
2.1.
|
“Yeda” shall mean Yeda Research and
Development Co. Ltd. of P.O. Box 95, Rehovot 76100,
Israel.
|
|
2.2.
|
“The
Company” shall mean XTL Biopharmaceuticals Ltd., of Kiryat
Weizmann, P.O. Box 370, Rehovot 76100, Israel.
|
|
2.3.
|
“The Main
Agreement” shall mean the Research and Licence Agreement
between Yeda and the Company, dated April 7, 1993.
|
|
2.4.
|
“The
Amendment Agreement” shall mean the Amendment of Research and
Licence Agreement dated August 31, 1995.
|
|
2.5.
|
“The
Research” shall mean the Research contemplated under the 1997
Research Programme.
|
|
2.6.
|
“The 1997
Research Programme” shall mean the research programme
attached hereto as Appendix 1.
|
***** Confidential
m
